Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Recruiting 3Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Carcinoma, Non-Small-Cell Lung 17Prostatic Neoplasms 12Lung Neoplasms 10Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms, Castration-Resistant 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Endometrial Neoplasms 4Neoplasms 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Salivary Gland Neoplasms 2Oropharyngeal Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Lymphoid Interstitial Pneumonia 2Carcinoma, Transitional Cell 2Carcinoma 2Anatomic Stage II Breast Cancer AJCC v8 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Neoplasms 1Urothelial Cancer 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7 1Stage I Prostate Adenocarcinoma AJCC v7 1Solid Tumors 1Small Cell Lung Carcinoma 1Selected Subjects With Advanced Solid Tumors 1

Interventions

Prednisone 5Docetaxel 4niraparib 2Abiraterone Acetate 2olaparib 1ibrutinib 1fludrocortisone acetate 1enzalutamide 1cabazitaxel 1abiraterone 1Rosuvastatin Calcium 1Pluvicto 1Pioglitazone 1JNJ-64619178 1JNJ-64264681 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Prostatic Neoplasms, Castration-Resistant × Docetaxel × 30 days × Clear all
NCT06353386 2026-05-26

MK-5684-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
220 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05848011 2026-05-22

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

MacroGenics

Phase 2 Completed
154 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT06863272 2026-05-15

IDeate-Prostate02

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
360 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT07225946 2026-05-11

KLK2-PASenger

Janssen Research & Development, LLC

Phase 3 Recruiting
800 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡